Mathew Garnett
Mathew Garnett
Wellcome Sanger Institute
Verified email at - Homepage
Cited by
Cited by
Mutations of the BRAF gene in human cancer
H Davies, GR Bignell, C Cox, P Stephens, S Edkins, S Clegg, J Teague, ...
Nature 417 (6892), 949-954, 2002
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan, MJ Garnett, SM Roe, S Lee, D Niculescu-Duvaz, VM Good, ...
Cell 116 (6), 855-867, 2004
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
W Yang, J Soares, P Greninger, EJ Edelman, H Lightfoot, S Forbes, ...
Nucleic acids research 41 (D1), D955-D961, 2012
Systematic identification of genomic markers of drug sensitivity in cancer cells
MJ Garnett, EJ Edelman, SJ Heidorn, CD Greenman, A Dastur, KW Lau, ...
Nature 483 (7391), 570-575, 2012
Prospective derivation of a living organoid biobank of colorectal cancer patients
M Van de Wetering, HE Francies, JM Francis, G Bounova, F Iorio, A Pronk, ...
Cell 161 (4), 933-945, 2015
A landscape of pharmacogenomic interactions in cancer
F Iorio, TA Knijnenburg, DJ Vis, GR Bignell, MP Menden, M Schubert, ...
Cell 166 (3), 740-754, 2016
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
L Broutier, G Mastrogiovanni, MMA Verstegen, HE Francies, LM Gavarrˇ, ...
Nature medicine 23 (12), 1424-1435, 2017
Guilty as charged: B-RAF is a human oncogene
MJ Garnett, R Marais
Cancer cell 6 (4), 313-319, 2004
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
FM Behan, F Iorio, G Picco, E Gonšalves, CM Beaver, G Migliardi, ...
Nature 568 (7753), 511-516, 2019
Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties
MP Menden, F Iorio, M Garnett, U McDermott, CH Benes, PJ Ballester, ...
PLoS one 8 (4), e61318, 2013
The advantages of targeted protein degradation over inhibition: an RTK case study
GM Burslem, BE Smith, AC Lai, S Jaime-Figueroa, DC McQuaid, ...
Cell chemical biology 25 (1), 67-77. e3, 2018
Perturbation-response genes reveal signaling footprints in cancer gene expression
M Schubert, B Klinger, M KlŘnemann, A Sieber, F Uhlitz, S Sauer, ...
Nature communications 9 (1), 20, 2018
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization
MJ Garnett, S Rana, H Paterson, D Barford, R Marais
Molecular cell 20 (6), 963-969, 2005
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling
S Huang, M H÷lzel, T Knijnenburg, A Schlicker, P Roepman, U McDermott, ...
Cell 151 (5), 937-950, 2012
A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds
A Bruna, OM Rueda, W Greenwood, AS Batra, M Callari, RN Batra, ...
Cell 167 (1), 260-274. e22, 2016
ETV6-NTRK3 Gene Fusions and Trisomy 11 Establish a Histogenetic Link between Mesoblastic Nephroma and Congenital Fibrosarcoma
SR Knezevich, MJ Garnett, TJ Pysher, JB Beckwith, PE Grundy, ...
Cancer research 58 (22), 5046-5048, 1998
Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis
M Petljak, LB Alexandrov, JS Brammeld, S Price, DC Wedge, ...
Cell 176 (6), 1282-1294. e20, 2019
Pancreatic cancer organoids recapitulate disease and allow personalized drug screening
E Driehuis, A Van Hoeck, K Moore, S Kolders, HE Francies, ...
Proceedings of the National Academy of Sciences 116 (52), 26580-26590, 2019
High-content CRISPR screening
C Bock, P Datlinger, F Chardon, MA Coelho, MB Dong, KA Lawson, T Lu, ...
Nature Reviews Methods Primers 2 (1), 1-23, 2022
Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics
X Li, HE Francies, M Secrier, J Perner, A Miremadi, N Galeano-Dalmau, ...
Nature communications 9 (1), 2983, 2018
The system can't perform the operation now. Try again later.
Articles 1–20